BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 33692943)

  • 1. Establishment and Characterization of an Irinotecan-Resistant Human Colon Cancer Cell Line.
    Wu ZX; Yang Y; Zeng L; Patel H; Bo L; Lin L; Chen ZS
    Front Oncol; 2020; 10():624954. PubMed ID: 33692943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poziotinib Inhibits the Efflux Activity of the ABCB1 and ABCG2 Transporters and the Expression of the ABCG2 Transporter Protein in Multidrug Resistant Colon Cancer Cells.
    Zhang Y; Wu ZX; Yang Y; Wang JQ; Li J; Sun Z; Teng QX; Ashby CR; Yang DH
    Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33158067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ABC-Transporter Expression Does Not Correlate with Response to Irinotecan in Patients with Metastatic Colorectal Cancer.
    Trumpi K; Emmink BL; Prins AM; van Oijen MG; van Diest PJ; Punt CJ; Koopman M; Kranenburg O; Rinkes IH
    J Cancer; 2015; 6(11):1079-86. PubMed ID: 26516354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
    Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
    Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases.
    Candeil L; Gourdier I; Peyron D; Vezzio N; Copois V; Bibeau F; Orsetti B; Scheffer GL; Ychou M; Khan QA; Pommier Y; Pau B; Martineau P; Del Rio M
    Int J Cancer; 2004 May; 109(6):848-54. PubMed ID: 15027118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
    Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
    Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ABCB1 and ABCG2 restricts the efficacy of gedatolisib (PF-05212384), a PI3K inhibitor in colorectal cancer cells.
    Liu C; Xing W; Yu H; Zhang W; Si T
    Cancer Cell Int; 2021 Feb; 21(1):108. PubMed ID: 33593355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance.
    Westover D; Ling X; Lam H; Welch J; Jin C; Gongora C; Del Rio M; Wani M; Li F
    Mol Cancer; 2015 Apr; 14():92. PubMed ID: 25928015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer.
    To KK; Leung WW; Ng SS
    Exp Cell Res; 2015 Nov; 338(2):222-31. PubMed ID: 26386386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.
    Gupta P; Zhang YK; Zhang XY; Wang YJ; Lu KW; Hall T; Peng R; Yang DH; Xie N; Chen ZS
    Cell Physiol Biochem; 2018; 45(4):1515-1528. PubMed ID: 29486476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal Effect of ALK Inhibitor NVP-TAE684 on ABCG2-Overexpressing Cancer Cells.
    Wang J; Wang JQ; Cai CY; Cui Q; Yang Y; Wu ZX; Dong X; Zeng L; Zhao L; Yang DH; Chen ZS
    Front Oncol; 2020; 10():228. PubMed ID: 32175279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
    Robey RW; Medina-Pérez WY; Nishiyama K; Lahusen T; Miyake K; Litman T; Senderowicz AM; Ross DD; Bates SE
    Clin Cancer Res; 2001 Jan; 7(1):145-52. PubMed ID: 11205902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to overcome multidrug resistance in vitro.
    Cihalova D; Staud F; Ceckova M
    Cancer Chemother Pharmacol; 2015 Jul; 76(1):105-16. PubMed ID: 25986678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment and Characterization of a Topotecan Resistant Non-small Cell Lung Cancer NCI-H460/TPT10 Cell Line.
    Lei ZN; Teng QX; Zhang W; Fan YF; Wang JQ; Cai CY; Lu KW; Yang DH; Wurpel JND; Chen ZS
    Front Cell Dev Biol; 2020; 8():607275. PubMed ID: 33425914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dinaciclib, a cyclin-dependent kinase inhibitor, is a substrate of human ABCB1 and ABCG2 and an inhibitor of human ABCC1 in vitro.
    Cihalova D; Ceckova M; Kucera R; Klimes J; Staud F
    Biochem Pharmacol; 2015 Dec; 98(3):465-72. PubMed ID: 26300056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. β-carotene reverses multidrug resistant cancer cells by selectively modulating human P-glycoprotein function.
    Teng YN; Sheu MJ; Hsieh YW; Wang RY; Chiang YC; Hung CC
    Phytomedicine; 2016 Mar; 23(3):316-23. PubMed ID: 26969385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo.
    Guo X; To KKW; Chen Z; Wang X; Zhang J; Luo M; Wang F; Yan S; Fu L
    J Exp Clin Cancer Res; 2018 Feb; 37(1):31. PubMed ID: 29458405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implications of ABCG2 Expression on Irinotecan Treatment of Colorectal Cancer Patients: A Review.
    Nielsen DL; Palshof JA; Brünner N; Stenvang J; Viuff BM
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28880238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VS-4718 Antagonizes Multidrug Resistance in ABCB1- and ABCG2-Overexpressing Cancer Cells by Inhibiting the Efflux Function of ABC Transporters.
    Ji N; Yang Y; Cai CY; Lei ZN; Wang JQ; Gupta P; Teng QX; Chen ZS; Kong D; Yang DH
    Front Pharmacol; 2018; 9():1236. PubMed ID: 30425643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.